Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 4,617.97% | 51.49% | -406.86% | 110.29% | -95.71% |
| Total Depreciation and Amortization | 0.00% | 0.00% | 0.00% | -96.67% | -0.90% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 138.42% | -457.72% | 1,876.74% | -100.78% | 162.00% |
| Change in Net Operating Assets | -10,048.05% | 56.35% | 106.30% | -446.18% | 2,400.87% |
| Cash from Operations | -73.29% | 19.55% | 63.06% | -17.61% | -29.82% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -100.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 228.15% | 82.87% | -164.22% | 37.47% | -15.91% |
| Cash from Investing | 261.57% | 86.42% | -164.18% | 37.55% | -15.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 608.48% | 94.31% | 86.31% | -83.73% | 95.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 608.48% | 94.31% | 86.31% | -83.73% | 95.92% |
| Foreign Exchange rate Adjustments | -1,100.00% | 108.33% | -157.14% | 425.00% | 112.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 229.50% | 70.67% | -4,565.48% | -54.96% | -83.36% |